Nanotechnology for virus treatment

Summary

This review and perspective considers how nanotechnology could improve treatment during viral outbreaks, especially before a matched vaccine is available. Vaccination can build population protection but is prophylactic and does not directly help someone who is already infected. Conventional antivirals can serve as an interim therapy, yet emerging strains may evade them and systemic adverse effects may outweigh benefit. The article surveys nanoscale strategies that address these weaknesses. Delivery vehicles can protect antiviral agents, improve their pharmacokinetic behavior, and reduce exposure outside the intended site, while other nanomaterials may directly inactivate viruses or act as neutralizing decoys. The review places these approaches in the immediate context of SARS-CoV-2 and then extends the discussion to preparedness for future pandemics. Its central synthesis is that nanotechnology contributes through multiple mechanisms rather than a single drug-carrier model: it can reformulate existing agents, create virus-binding materials, or provide virucidal activity. The significance is a flexible therapeutic toolkit for the interval when vaccines or strain-specific medicines are inadequate. The abstract does not evaluate particular products comparatively or provide clinical evidence, safety rankings, development timelines, or proof that these concepts work against future unknown viruses.